A new approach to analyzing cell membrane proteins in situ could revolutionize the way in which we study diseases, such as cancer, metabolic and heart diseases.

The pair of Colorado State University organic chemists have forged a powerful new tool for drug hunters - a simple, elegantly designed chemical reaction that could fling open an underexplored wing of biologically relevant chemistry.

A new Tel Aviv University study finds that the drug candidate CP201, also known as NAP, may improve vocal communication abilities that are underdeveloped in Activity-dependent neuroprotective protein (ADNP) patients.

A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.

Clinically relevant eradication of leukemia stem cells could be achieved with drugs that target their metabolic vulnerabilities.

Researchers at IRB Barcelona modify chlorotoxin—a small protein present in scorpion venom with blood-brain barrier permeability—to transport drugs into the brain.

In this article, we explore two novel high-throughput analytical methods based on liquid chromatography-mass spectrometry (LC-MS) analysis that can augment early drug screening and biomarker detection in the clinic.

The development of new in vitro models to replace in vivo testing has already proven quite successful for certain targets. Among these are models of the immune system and human skin, while in vitro cardiac arrhythmia models are poised to emerge in the near future. Despite this clear progress, an efficient model for liver organ toxicity testing still remains elusive.

To achieve regulatory compliance and authorization for sale in Europe, every medical device must be supported by a Clinical Evaluation Report which documents the entire clinical evaluation process. Read on for recommendations on how manufacturers can keep up with the changing regulation landscape.

The rate at which new drugs are discovered is in decline, and computer-aided drug design has not produced the radical change in the success of candidate drugs the pharma industry anticipated. Artificial intelligence (AI)-based approaches are the new hope for revolutionizing the drug discovery process. But are these, as computer-aided drug design was, an over-hyped time bomb waiting to be found out? Or is it truly a revolution on the cusp of realizing its promise?

As part of the host-pathogen arms race, viruses are continually evolving to evade the host immune response, be it from previous infection or immunity acquired through vaccination. Here we take a look at the processes of antigenic drift and antigenic shift.

Changes to the complex of DNA and the proteins that form chromatin are important drivers in many cancers. We explore the challenges and progress in the development of new therapies targeting epigenetic regulators.